Navigation
Open Access
Review
Neuroprotective agents and modulation of temporal lobe epilepsy
Maria Jose da Silva Fernandes1,*,Jose Eduardo Marques-Carneiro1,Rebeca Padrão Amorim1,Leão Araujo Michelle Gasparetti1,Astrid Nehlig2
1
Department of Neurology and Neurosurgery, Universidade Federal de Sao Paulo-UNIFESP, Rua Pedro de Toledo, 669 - 2º andar, CEP 04039-032, Sao Paulo, SP, Brazil
2
Inserm U-666, Strasbourg, France
DOI: 10.2741/E719 Volume 7 Issue 1, pp.90-106
Published: 01 January 2015
(This article belongs to the Special Issue Current advances in epilepsy and neurodegeneration)
*Corresponding Author(s):  
Maria Jose da Silva Fernandes
E-mail:  
fernandesepm@gmail.com
Abstract

Temporal Lobe Epilepsy (TLE) is a chronic condition characterized by epileptic seizures originating mainly in temporal lobe areas. Epileptogenesis is a process in which a central nervous system injury can lead surviving neuronal populations to generate abnormal, synchronous and recurrent epileptiform discharges producing focal or generalized seizures. Hipocampal sclerosis, a massive cell death in the hippocampal formation and in the other regions of temporal lobe, is considered as hallmark of TLE. Despite the numerous antiepileptic drugs (AEDs) commercially available, about 30-40% of patients remain with seizures refractory to pharmacological treatment. In addition, there is no drug with significant efficacy to modify the epileptogenesis process. In this review we present some data regarding the neuroprotective effect of some adenosinergic agents, erythropoietin and carisbamate regarding the disease- and epileptogenesis-modifying effect.

Key words
Temporal Lobe Epilepsy,Neuroprotection,Erytropoietin,Adenosine,Carisbamate,Review
Share and Cite
Maria Jose da Silva Fernandes, Jose Eduardo Marques-Carneiro, Rebeca Padrão Amorim, Leão Araujo Michelle Gasparetti, Astrid Nehlig. Neuroprotective agents and modulation of temporal lobe epilepsy. Frontiers in Bioscience-Elite. 2015. 7(1); 90-106.